Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

被引：0
|
作者：
Caffo, O. [1 ]
Biasco, E. [2 ]
Facchini, G. [3 ]
Fratino, L. [4 ]
Gasparro, D. [5 ]
Mosillo, C. [6 ]
Maruzzo, M. [7 ]
Santini, D. [8 ]
Tucci, M. [9 ]
Ortega, C. [10 ]
Verderame, F. [11 ]
Scagliarini, S. [12 ]
Lo Re, G. [13 ]
Procopio, G. [14 ]
Fornarini, G. [15 ]
Campadelli, E. [16 ]
Sabbatini, R. [17 ]
Maines, F. [1 ]
De Giorgi, U. [18 ]
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] Osped Santa Chiara, Pisa, Italy
[3] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[4] Ctr Riferimento Oncol, Aviano, Italy
[5] Azienda Osped Univ, Parma, Italy
[6] Univ Roma La Sapienza, Rome, Italy
[7] Ist Oncol Veneto, Padua, Italy
[8] Univ Campus Biomed, Rome, Italy
[9] Osped San Luigi, Orbassano, Italy
[10] IRCCS, Candiolo, Italy
[11] Osped Villa Sofia Cervello, Palermo, Italy
[12] Osped Cardarelli, Naples, Italy
[13] Osped Santa Maria Angeli, Pordenone, Italy
[14] Fdn Ist Nazl Tumori, Milan, Italy
[15] Osped San Martino Genova, Genoa, Italy
[16] Osped Gen, Lugo Di Romagna, Spain
[17] Azienda Osped Univ, Modena, Italy
[18] IRST, Meldola, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw334.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C09
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.
    Veccia, Antonello
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Alesini, Daniele
    Basso, Umberto
    Tucci, Marcello
    Ortega, Cinzia
    Scagliarini, Sarah
    Verderame, Francesco
    Lo Re, Giovanni
    Procopio, Giuseppe
    Sabbatini, Roberto
    Campadelli, Enrico
    Zucali, Paolo Andrea
    Morelli, Franco
    Sartori, Donata
    Conteduca, Vincenza
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [32] Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Burgio, Salvatore Luca
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Zustovich, Fable
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Donini, Maddalena
    Bortolus, Roberto
    Vicario, Giovanni
    Zucali, Paolo A.
    Basso, Umberto
    Lo Re, Giovanni
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [33] Outcomes of elderly patients (pts) treated with docetaxel (DOC) for metastatic castration-sensitive prostate cancer (mCSPC): Results from ECHOS, a multicenter Italian observational study.
    Caffo, Orazio
    Maruzzo, Marco
    Pravisano, Federico
    Buttigliero, Consuelo
    Soraru, Mariella
    Masini, Cristina
    Gori, Stefania
    Sabbatini, Roberto
    Pappalardo, Annalisa
    Cattrini, Carlo
    Fornarini, Giuseppe
    Vittimberga, Isabella
    Rametta, Alessandro
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Grillone, Francesco
    Fratino, Lucia
    Galli, Luca
    Giordano, Monica
    Basso, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 153 - 153
  • [34] Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
    Van Praet, Charles
    Rottey, Sylvie
    Van Hende, Fransien
    Pelgrims, Gino
    Demey, Wim
    Van Aelst, Filip
    Wynendaele, Wim
    Gil, Thierry
    Schatteman, Peter
    Filleul, Bertrand
    Schallier, Denis
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Everaert, Els
    D'Hondt, Lionel
    Werbrouck, Patrick
    Vermeij, Joanna
    Mebis, Jeroen
    Clausse, Marylene
    Rasschaert, Marika
    Van Erps, Joanna
    Verheezen, Jolanda
    Van Haverbeke, Jan
    Goeminne, Jean-Charles
    Lumen, Nicolaas
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : 502 - 508
  • [35] When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
    Procopio, G.
    Porcu, L.
    Grassi, P.
    De Giorgi, U.
    Galli, L.
    Caffo, O.
    Boccardo, F.
    Facchini, G.
    De Vincenzo, F.
    Zaniboni, A.
    Chiuri, V.
    Fratino, L.
    Santini, D.
    Adamo, V.
    De Vivo, R.
    Di Nota, A.
    Messina, C.
    Ricotta, R.
    de Braud, F.
    Verzoni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 59 - 59
  • [36] Impact of prior antiandrogen exposure on clinical outcomes in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Bellmunt, J.
    Yu, M. K.
    Kheoh, T.
    Taplin, M. E.
    Davis, I. D.
    Schnjvers, D.
    Protheroe, A.
    Molina, A.
    De Bono, J. S.
    Scher, H. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S695 - S695
  • [37] Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
    Lozano Mejorada, R.
    Lorente, D.
    Castro, E.
    Bianchini, D.
    Nombela, P.
    Sandhu, S. K.
    Romero Laorden, N.
    Cendon, Y.
    Sharp, A.
    Almagro Casado, E.
    Pacheco, M. I.
    Rescigno, P.
    Llacer, C.
    Saez, M.
    Rivera, L.
    Vitrone, F.
    Moreno, C.
    Mateo, J.
    de Bono, J. S.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 350 - 350
  • [38] Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).
    Caffo, Orazio
    Wissing, Michel
    Bianchini, Diletta
    Bergman, Andre M.
    Thomsen, Frederik BirkebAk
    Schmid, Sebastian
    Yu, Evan Y.
    Bournakis, Evangelos
    Sella, Avishay
    Basso, Umberto
    De Giorgi, Ugo
    Tucci, Marcello
    Gelderblom, Hans
    Galli, Luca
    Sperduti, Isabella
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Clinical outcomes (CO) evaluation of very old (≥80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Updated results of an Italian multicenter retrospective study (cooperative group for DELPHI study)
    Caffo, O.
    Burgio, L. S.
    Di Lorenzo, G.
    Ortega, C.
    Scognamiglio, F.
    Mattioli, R.
    Mansueto, G.
    Facchini, G.
    Zustovich, F.
    Maines, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S699 - S699
  • [40] Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study
    Omrcen, Tomislav
    Eterovic, Davor
    Vrdoljak, Eduard
    ANTI-CANCER DRUGS, 2020, 31 (07) : 742 - 746
12345